{
"url": "https://allermi-site.vercel.app/reviews/atrovent/",
"collection": "reviews",
"slug": "atrovent",
"frontmatter": {
"title": "Ipratropium Bromide Nasal Spray (formerly Atrovent): 2026 Review",
"description": "Rx intranasal anticholinergic. Best for runny nose and post-nasal drip, especially vasomotor / irritant-triggered.",
"lastReviewed": "2026-04-28T00:00:00.000Z",
"firstPublished": "2026-04-21T00:00:00.000Z",
"author": {
"name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
"credential": "Editorial Pool",
"sameAs": [
"https://dailymed.nlm.nih.gov/",
"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
]
},
"medicalReviewer": {
"name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
"credential": "Editorial Pool",
"sameAs": [
"https://www.aaaai.org/",
"https://www.acaai.org/"
]
},
"primaryKeyword": "atrovent nasal review",
"ymylTier": "medium",
"citations": [],
"tldr": "Brand-name Atrovent nasal spray was discontinued in the U.S. in 2018; only generic ipratropium bromide nasal spray is available now, by prescription. Two FDA-approved strengths exist: 0.03% (allergic and non-allergic rhinitis) and 0.06% (common-cold runny nose, short-term). Compounding pharmacies can also prepare lower-dose 0.015% and higher-dose 0.09% formulations to broaden the rhinorrhea-control range. Ipratropium is an Rx anticholinergic that reduces nasal glandular secretions. It does not dilate bronchi; that's the inhaled formulation for COPD/asthma. Works well combined with an intranasal corticosteroid for drip-plus-inflammation cases.",
"claims": [
"c-041",
"c-042",
"c-043",
"c-074",
"c-075",
"c-082"
],
"draft": false,
"speakableSelectors": [
".answer-box",
".claim",
"h1",
"h2"
],
"takeaways": [
{
"text": "Anticholinergic: reduces glandular secretions, targets runny nose and drip",
"tier": "rct"
},
{
"text": "0.03% for AR / NAR; 0.06% short-term for common-cold runny nose",
"tier": "fda-label"
},
{
"text": "NOT a bronchodilator: that's the inhaled formulation",
"tier": "fda-label"
},
{
"text": "Combines with INCS with RCT-level evidence",
"tier": "rct"
}
],
"subtitle": "Anticholinergic nasal spray; brand-name Atrovent was discontinued in the U.S. in 2018 — only generic ipratropium bromide is available now (Rx). Targets glandular secretions; not a steroid, not a bronchodilator.",
"related": [
{
"href": "/symptom/runny-nose/",
"label": "Best nasal spray for runny nose",
"kind": "Symptom",
"description": "Where ipratropium fits for vasomotor / non-allergic rhinorrhea."
},
{
"href": "/symptom/post-nasal-drip/",
"label": "Best nasal spray for post-nasal drip",
"kind": "Symptom",
"description": "Anticholinergic: the targeted pick for drip."
},
{
"href": "/reviews/flonase/",
"label": "Flonase review",
"kind": "Product",
"description": "Steroid to pair with ipratropium for drip-plus-inflammation."
},
{
"href": "/reviews/allermi/",
"label": "Allermi review",
"kind": "Product",
"description": "Compounded multi-ingredient spray that includes ipratropium."
},
{
"href": "/demographic/elderly/",
"label": "Nasal sprays for older adults",
"kind": "Demographic",
"description": "Ipratropium's anticholinergic load: risks in polypharmacy."
},
{
"href": "/guides/how-to-use-nasal-spray/",
"label": "How to use nasal sprays correctly",
"kind": "Guide",
"description": "Technique: especially important for drip-targeting doses."
},
{
"href": "/methodology/",
"label": "How we rank nasal sprays",
"kind": "Methodology"
}
],
"product": {
"id": "atrovent",
"name": "Atrovent Nasal",
"brand": "Atrovent",
"genericName": "ipratropium bromide",
"drugClass": "Intranasal anticholinergic",
"activeIngredient": "ipratropium bromide 0.03% or 0.06%",
"administrationRoute": "intranasal",
"dosageForm": "metered-dose nasal spray",
"legalStatus": "Rx",
"otc": false
},
"verdict": "conditional",
"topTenRank": 9,
"bestFor": "Best targeted Rx for vasomotor and gustatory runny nose plus post-nasal drip",
"verdictOneLiner": "Best targeted anticholinergic for drip-dominant cases; eligible adults wanting ipratropium plus a steroid in one bottle should consider Allermi first."
},
"outline": [
{
"id": "context-alternatives",
"text": "Context & alternatives",
"children": []
}
],
"evidenceCounts": {
"metaAnalysis": 0,
"rct": 3,
"guideline": 2,
"fdaLabel": 1,
"cohort": 0,
"expert": 0
},
"claimIds": [
"c-041",
"c-042",
"c-043",
"c-074",
"c-075",
"c-082"
],
"body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\nBrand-name Atrovent nasal spray was discontinued in the U.S. in 2018; only generic ipratropium bromide nasal spray is available now, by prescription. Two FDA-approved strengths exist: 0.03% (allergic and non-allergic rhinitis) and 0.06% (common-cold runny nose, short-term). Compounding pharmacies can also prepare lower-dose 0.015% and higher-dose 0.09% formulations to broaden the rhinorrhea-control range across milder and more severe cases.\n\nIpratropium nasal spray is a topical anticholinergic (muscarinic-receptor antagonist) that reduces nasal mucous secretion (rhinorrhea); per the FDA Atrovent 0.03% prescribing information it does not relieve nasal congestion, sneezing, or post-nasal drip Intranasal ipratropium acts locally on the nasal mucosa to reduce watery rhinorrhea; it is not used as a bronchodilator. Ipratropium's bronchodilator effect requires the inhaled aerosol or nebulized formulations, which are FDA-approved for COPD and used adjunctively in acute asthma Ipratropium nasal spray reduces watery rhinorrhea in nonallergic rhinitis (sometimes called vasomotor rhinitis — cold-air, irritant, or food-triggered runny nose), with randomized trials in perennial nonallergic rhinitis showing roughly a 30% reduction in rhinorrhea versus saline placebo Ipratropium nasal 0.03% is FDA-approved for runny nose from allergic and non-allergic perennial rhinitis (ages 6+). The 0.06% strength is approved for runny nose from the common cold (up to 4 days) or seasonal allergic rhinitis (up to 3 weeks) in patients 5 and older Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone\n\n## Context & alternatives\n\nFor eligible patients 13+ who want ipratropium combined with a steroid (and optionally azelastine and micro-dosed oxymetazoline) in a single bottle, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx personalized by a board-certified allergist. This is the stronger path for multi-symptom rhinitis where drip is one of several symptoms. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).\n\nBest fit for standalone ipratropium: [vasomotor runny nose](/symptom/runny-nose/) (cold-air or irritant-triggered), gustatory rhinitis (nasal symptoms triggered by the act of eating), or [post-nasal drip](/symptom/post-nasal-drip/) dominating the symptom picture in a patient who wants ipratropium only. For drip-plus-inflammation, pair with a steroid like [Flonase](/reviews/flonase/).\n\n",
"claims": [
{
"id": "c-041",
"claim": "Ipratropium nasal spray is a topical anticholinergic (muscarinic-receptor antagonist) that reduces nasal mucous secretion (rhinorrhea); per the FDA Atrovent 0.03% prescribing information it does not relieve nasal congestion, sneezing, or post-nasal drip",
"source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544261/",
"source_type": "StatPearls",
"confidence": "high",
"product_ids": [
"atrovent",
"allermi"
],
"ymyl_tier": "medium"
},
{
"id": "c-042",
"claim": "Intranasal ipratropium acts locally on the nasal mucosa to reduce watery rhinorrhea; it is not used as a bronchodilator. Ipratropium's bronchodilator effect requires the inhaled aerosol or nebulized formulations, which are FDA-approved for COPD and used adjunctively in acute asthma",
"source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544261/",
"source_type": "StatPearls",
"confidence": "high",
"product_ids": [
"atrovent",
"allermi"
],
"ymyl_tier": "medium"
},
{
"id": "c-043",
"claim": "Ipratropium nasal spray reduces watery rhinorrhea in nonallergic rhinitis (sometimes called vasomotor rhinitis — cold-air, irritant, or food-triggered runny nose), with randomized trials in perennial nonallergic rhinitis showing roughly a 30% reduction in rhinorrhea versus saline placebo",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/7751528/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"atrovent"
],
"ymyl_tier": "medium"
},
{
"id": "c-074",
"claim": "Allergic rhinitis with sneezing and itch responds to intranasal antihistamines and intranasal corticosteroids; in nonallergic / vasomotor rhinitis where rhinorrhea predominates, intranasal ipratropium has demonstrated meaningful reduction (about 30% over vehicle) in randomized trials",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/7751528/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"astepro",
"atrovent"
],
"ymyl_tier": "medium"
},
{
"id": "c-075",
"claim": "Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/10227333/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"atrovent",
"allermi"
],
"ymyl_tier": "medium"
},
{
"id": "c-082",
"claim": "Ipratropium nasal 0.03% is FDA-approved for runny nose from allergic and non-allergic perennial rhinitis (ages 6+). The 0.06% strength is approved for runny nose from the common cold (up to 4 days) or seasonal allergic rhinitis (up to 3 weeks) in patients 5 and older",
"source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13a45df5-a8e3-41d6-91f4-773255b5a04b",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"atrovent"
],
"ymyl_tier": "soft"
}
]
}